Skip to main content

Table 6 Optimal HBV-derived HLA class I restricted CTL epitopes

From: Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Protein

HLA Restriction

Sequence

Position

Reference

Core

A2

FLPSDFFPSV

18–27

[84]

Core

A2

CLTFGRETV

107–115

[85]

Core

A2

VLEYLVSFGV

115–124

[85]

Core

A2/A24

EYLVSFGVW

117–125

[86, 87]

Core

A2

ILSTLPETTV

139–148

[86]

Core

A33/A68

STLPETTVVRR

141–151

[88]

Core

A2

AILSKTGDPV

152–161

[89]

Env

A2

LLDPRVRGL

131–139

[85]

Env

A2

VLQAGFFLL

177–185

[90]

Env

A2

FLLTRILTI

183–191

[91]

Env

A2

SLNFLGGTTV

201–210

[92]

Env

A2

FLGGTPVCL

204–212

[89]

Env

A2

LLLCLIFLL

250–258

[86]

Env

A2

LLCLIFLLV

251–259

[92]

Env

A2

LLDYQGMLPV

260–269

[92]

Env

A2

LVLLDYQGML

269–278

[85]

Env

A2

VLLDYQGML

270–278

[85]

Env

A2

LLDYQGMLPV

271–280

[85]

Env

A2

WLSLLVPFV

335–343

[92]

Env

A2

LLVPFVQWFV

338–347

[92]

Env

A2

GLSPTVWLSV

348–357

[92]

Env

A2

SIVSPFIPLL

370–379

[89]

Env

A2

LLPIFFCLWV

378–387

[92]

Env

A2

ILSPFFFLPLL

382–390

[85]

x-Protein

A2

VLCLRPVGA

15–23

[93]

x-Protein

A2

TLPSPSSSA

36–44

[93]

x-Protein

A2

HLSLRGLFV

52–60

[93]

x-Protein

A2

VLHKRTLGL

92–100

[93]

x-Protein

A2

AMSTTDLEA

102–110

[93]

x-Protein

A2

CLFKDWEEL

115–123

[93]

Pol

A24

LYSSTVPVF

62–70

[90]

Pol

A2

GLSRYVARL

455–463

[90]

Pol

A2

YMDDVVLGA

551–559

[91]

Pol

A2

FLLSLGIHL

575–583

[90]

Pol

A24

KYTSFPWLL

756–764

[87]

Pol

A2

ILRGTSFVYV

773–782

[91]

Pol

A2

SLYADSPSV

816–824

[91]